In 2017, the Oxford AHSN initiated a project to increase uptake and adoption of placental growth factor-based (PlGF) testing which highlights women who are likely to develop pre-eclampsia within 7-14 days.
The Oxford AHSN helped three of the first hospitals in England to adopt PlGF blood tests into standard clinical practice, working with the Oxford Patient Safety Collaborative and clinical leads, laboratory heads, finance and management functions.
This demonstrated that by offering tests to women suspected of having pre-eclampsia clinical teams were better able to identify women who did not have the disease and could safely go home, avoiding unnecessary hospital admissions for monitoring. These results provided a platform for wider spread and adoption.
The test was selected for the NHS England Accelerated Access Collaborative, Innovation Technology Payment and Rapid Uptake programmes which introduce an accelerated pathway to market for highly transformative innovations. In 2021 PlGF-based testing was one of four technologies included under the new NHS MedTech Funding Mandate.
All AHSNs have been working together to ensure rapid and widespread adoption of the test into standard clinical practice in maternity units across England.